India is the second largest drug exporter to the US, according to the Food and Drug Administration (FDA).The increased fees would be effective from October 1, 2013.
WASHINGTON: Many Indian drugmakers will soon have to bear higher costs for sale of products in American markets, as the US health regulator FDA is hiking the fees for generic drugmakers by up to 48 per cent from October.
India is the second largest drug exporter to the US, according to the Food and Drug Administration (FDA).
Indian drugmakers mostly specialise in manufacturing of generic versions of innovative drugs at a fraction of cost after their patent expiry and are estimated to command 10 per cent share in the USD 30-billion US generic drug market.
India is the second largest drug exporter to the US, according to the Food and Drug Administration (FDA).
Indian drugmakers mostly specialise in manufacturing of generic versions of innovative drugs at a fraction of cost after their patent expiry and are estimated to command 10 per cent share in the USD 30-billion US generic drug market.
0 comments:
Post a Comment